← Back to Screener
Scienture Holdings, Inc. Common Stock (SCNX)
Price$0.42
Favorite Metrics
Price vs S&P 500 (26W)-52.41%
Price vs S&P 500 (4W)-27.20%
Market Capitalization$16.05M
P/E Ratio (Annual)1.33x
All Metrics
Book Value / Share (Quarterly)$1.73
P/TBV (Annual)16.60x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-66.47%
Cash Flow / Share (Quarterly)$-0.33
Price vs S&P 500 (YTD)-26.69%
Gross Margin (TTM)88.48%
Net Profit Margin (TTM)-2117.28%
EPS (TTM)$-1.72
10-Day Avg Trading Volume0.58M
EPS Excl Extra (TTM)$-1.72
Revenue Growth (5Y)-52.10%
EPS (Annual)$-2.70
Dividend / Share (Annual)$3.08
ROI (Annual)-58.46%
Gross Margin (Annual)76.80%
Net Profit Margin (5Y Avg)-656.60%
Cash / Share (Quarterly)$0.16
Revenue Growth QoQ (YoY)809.73%
P/E Normalized (Annual)1.33x
ROA (Last FY)-49.31%
Revenue Growth TTM (YoY)-73.18%
EBITD / Share (TTM)$-1.47
ROE (5Y Avg)-787.09%
Operating Margin (TTM)-2234.99%
Cash Flow / Share (Annual)$-0.33
P/B Ratio0.23x
P/B Ratio (Quarterly)0.30x
Net Income / Employee (Annual)$-3
Net Interest Coverage (TTM)-28.32x
ROA (TTM)-19.56%
EPS Incl Extra (Annual)$-2.70
Current Ratio (Annual)2.89x
Quick Ratio (Quarterly)2.72x
3-Month Avg Trading Volume2.73M
52-Week Price Return-56.27%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.27
P/S Ratio (Annual)37.18x
Asset Turnover (Annual)0.01x
52-Week High$2.60
Operating Margin (5Y Avg)-4536.17%
EPS Excl Extra (Annual)$-2.70
CapEx CAGR (5Y)99.24%
26-Week Price Return-43.66%
Quick Ratio (Annual)2.72x
13-Week Price Return-23.32%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)2.89x
Enterprise Value$10.272
Revenue / Share Growth (5Y)-75.76%
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)21.74x
Pretax Margin (Annual)-10080.20%
Cash / Share (Annual)$0.16
3-Month Return Std Dev126.21%
Gross Margin (5Y Avg)35.48%
Net Income / Employee (TTM)$-1
ROE (Last FY)-59.20%
Net Interest Coverage (Annual)-7.77x
EPS Basic Excl Extra (Annual)$-2.70
P/FCF (TTM)3.80x
Receivables Turnover (TTM)2.18x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-1.72
Receivables Turnover (Annual)1.16x
ROI (TTM)-24.41%
P/S Ratio (TTM)24.56x
Pretax Margin (5Y Avg)-4802.80%
Revenue / Share (Annual)$0.03
Tangible BV / Share (Annual)$0.31
Price vs S&P 500 (52W)-91.36%
Year-to-Date Return-22.55%
5-Day Price Return15.16%
EPS Normalized (Annual)$-2.70
ROA (5Y Avg)-73.75%
Net Profit Margin (Annual)-9618.00%
Month-to-Date Return38.60%
EBITD / Share (Annual)$-2.74
Operating Margin (Annual)-9947.06%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-143.11%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.72
P/TBV (Quarterly)2.86x
Payout Ratio (Annual)163.90%
P/B Ratio (Annual)0.30x
Dividend / Share (TTM)$0.25
Inventory Turnover (TTM)0.62x
Pretax Margin (TTM)-2143.97%
Book Value / Share (Annual)$1.73
Price vs S&P 500 (13W)-26.18%
Dividend Yield (TTM)13.63%
Beta3.10x
P/FCF (Annual)267.49x
Revenue / Share (TTM)$0.03
ROE (TTM)-25.63%
52-Week Low$0.24
Analyst Recommendations
Feb 2024
Mar 2024
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SCNXScienture Holdings, Inc. Common Stock | 24.56x | -73.18% | 88.48% | — | $0.42 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Scienture Holdings Inc develops specialty pharmaceutical products and healthcare services to address unmet market needs in the United States. The company emphasizes enhancing patient engagement and streamlining the prescription experience, delivering value to patients, caregivers, and providers.